Press Coverage
Sofinnova Telethon
Sofinnova Partners charging ahead in Italy
Related Deal lead
Graziano SeghezziRelated Strategy
TelethonCorriere Della Sera, the leading Italian daily, published an article Nov. 22 detailing how Sofinnova Partners is "charging ahead" in Italy, investing €46 million in the country over 2 years and picking up an increasing number of local investors for Sofinnova Partners' Italian projects, the Sofinnova Telethon Strategy and the BiovelocIta accelerator.
"All the work we have done in Italy since 2015 has borne fruit," Graziano Seghezzi, managing partner at Sofinnova Partners, is quoted as saying. "We closed more than half of the 15 investments announced. We tripled the number of Italian investors in our fund, now they are 17 between institutional investors and family offices.”
Seghezzi pointed out that Sofinnova’s Milan offices house the “largest team in Italy dedicated to biotechnology” and that the company assessed 500 investments in Italy over the past three years.
Read the original article, written by Alessandra Puato and published in the weekly insert L'Economia (In Italian).
Related News
AAVantgarde Receives FDA IND Clearance to Progress Stargardt Disease program AAVB-039
Tenpoint Therapeutics Ltd. Announces FDA Acceptance of New Drug Application for BRIMOCHOL™ PF for the Treatment of Presbyopia
Enthera Pharmaceuticals Announces Publication in the Journal of Clinical Investigation Supporting the Clinical Development of Ebrasodebart
GlycoEra AG raises $130 million to advance novel pipeline of extracellular protein degraders for the treatment of autoimmune diseases
AAVantgarde presents positive clinical data from its AAVB-081 program for Usher 1B and preclinical data from its AAVB-039 program for Stargardt at the ARVO 2025 annual meeting